A B S T R A C T A 17 yr old female with a congenital bleeding disorder was found to suffer from dysfibrinogenemia. Whole blood and plasma coagulation times were delayed and thrombelastograms were grossly abnormal. Clottability of plasma fibrinogen by addition of thrombin was not demonstrated during the 30 min test period. Fibrinogen was revealed by turbidometric and immunologic techniques. Other coagulation factors were present in normal amounts and prothrombin activation was normal. Patient's plasma inhibited thrombin clotting times of normal plasma and purified normal fibrinogen. Fibrinolysis was not detected.
mal fibrinogen. Purified normal fibrinogen (clottability 96.7%) and "Fibrinogen Detroit" revealed homogeneity when studied by ultracentrifugation and immunoelectrophoresis. Native and cleaved "Fibrinogen Detroit" had the same sedimentation constants and molecular weights as the normal. In fresh samples, 3 moles of free SH groups/mole of fibrinogen were titrated in both. Determination of the amino acid composition revealed a decreased content of lysine, glucosamine, and galactosamine in abnormal fibrinogen. Total carbohydrates, protein-bound hexoses, sialic acid, and hexosamine were decreased in the abnormal fibrinogen.
In an investigation with Doctors Blomback a specific molecular defect was revealed in the N-terminal disulfide knot of the alpha (A) chain in which the arginine at the 19th position was replaced by serine. It is believed that the substitution of a strongly basic amino acid with a neutral hydroxy acid may result in considerable conformational changes in the N-terminal disulfide knot of fibrinogen which might affect the "active site" for polymerization. The lower carbohydrate content observed in "Fibrinogen Detroit" may have been the result of a change in primary and tertiary structure of the protein.
Whole blood clotting times were normal, but friable clots were observed. There were electrophoretic differences between the patient's fibrinogen and normal fibrinogen (4, 5) . In view of certain differences among these patients with dysfibrinogenemia thus far described, Beck and coworkers (3) (4) (5) (6) recommended the adoption of a nomenclature similar to the one used for the description of hemoglobinopathies, and termed their abnormal fibrinogen "Fibrinogen Baltimore."
In 1964 von Felten, Duckert, and Frick (7) described a fourth family with an abnormal fibrinogen. A recent reinvestigation of a family previously described as "congenital hypofibrinogenemia" (8) by Beck and Thomas [cited from (6) ] revealed that the family suffered from dysfibrinogenemia. The pattern of heredity seemed to be autosomal dominant (8) , and the affected family members displayed a mild bleeding tendency. Forman, Boyer, and Ratnoff (9) described the sixth family with an abnormal fibrinogen. The defect seemed to lie in the aggregation of the fibrin monomers. The patient's fibrinogen was distinguishable from normal fibrinogen and "Fibrinogen Baltimore" by immunoelectrophoresis and was termed "Fibrinogen Cleveland. " This report concerns a Detroit Negro family with an abnormal fibrinogen molecule, which we propose to term "Fibrinogen Detroit." Immunological and physicochemical properties of this fibrinogen also are presented in this paper. Case history. P. H., a 17 yr old Negro female, was admitted to Detroit General Hospital in June 1966 as a referral because of anemia after excessive blood loss during menstruation. Menarche was at age 11. Menstruation was irregular, required use of 7-20 pads a day and flow lasted from 7 to 12 days.
The past history revealed that in July 1965 she was admitted to Detroit General Hospital for the first time on Obstetrics and Gynecology Service because of excessive menstrual bleeding and her hemoglobin was 4.2 g/100 ml. Detailed physical and pelvic examinations and routine blood tests failed to reveal any abnormality. No clotting studies were performed at that time. Cervical curettings showed normal secretory endometrium. She was transfused with 4 U of whole blood and on discharge the hemoglobin was 12 g/100 ml. She was subsequently seen by Gynecological Service for repeated episodes of anemia after excessive menstrual bleeding for which she received blood transfusions on two different occasions before her admission in June 1966. Because of menstrual difficulties her physician prescribed Norinyl1 (progesterone, 1 mg, with estrogen ethinyl estradiol 3 methylether 0.05 mg), 1 tablet daily for 20 days each menstrual cycle. She apparently did fairly well until 1 Syntex Laboratories, Inc., Stanford Industrial Park, Palo Alto, Calif. June 1966 although she had discontinued the hormonal therapy after two months and had failed to return to the clinic.
Family history revealed that her 35 yr old mother (E.H.) also suffered from excessive menstrual bleeding and mild hemorrhages after minor injuries since early childhood. She also gave a history of several episodes of epistaxis. In spite of these bleeding tendencies, she delivered nine children without any serious complications. Two brothers of P. H., one 2. Immunologic studies. Antihuman fibrinogen was prepared in rabbits according to Barnhart, Anderson, and Baker (29) by injection of microgram quantities of purified human fibrinogen (>96% clottable and homogeneous according to immunoelectrophoresis against antiplasma). The antiserum obtained had a precipitin titer of 1/16384 against 1% fibrinogen. This antifibrinogen formed only one precipitin band when reacted against plasma and purified fibrinogen in agar plates and on immunoelectrophoresis. No reaction occurred when this antifibrinogen was tested against purified albumin, prothrombin, profibrinolysin, or gamma globulin IgG (0.01-1%).
Quantitative immunoprecipitin assays (23, 30) gave a measure of total fibrinogen-related material in plasma and nonclottable fibrinogen-related molecules in serum. An essential feature for accurate determination is excess antibody in the system. Goodman, Wolfe, and Norton (31) established that turbidometric analysis of formed immunoprecipitins was in good agreement with the quantitative precipitin test of Heidelberger and Kendall (32) where the collected antigen-antibody complexes were subjected to nitrogen determination. Our test system is detailed in another publication (30) but the important features are briefly presented here. Nonclottable fibrinogen-related molecules were measured after recalcification or addition of purified thrombin to produce serum. The defibrination phase lasted 30-60 min. Serial dilutions (1/10-1/640) were prepared from either the serum supernatant or plasma by adding saline (Sherman Laboratories, Detroit, Mich., low particle content). To test tubes containing 4.6 ml saline was added 0.1 ml of the diluted serum or plasma and 0.3 ml of standardized antifibrinogen serum (30) . After thorough mixing of the reagents the tube was incubated for 1 hr at 370C. Approximately 100 mg of fibrinogen was placed on each of two Sephadex G-50e columns (2.5 X 65 cm) at room temperature previously washed with 0.9% NaCl solution. Elution followed with 0.9% NaCl solution. Fractions of 12-ml volume were collected. The protein emerged rapidly from the column before the (NH4)2SO4 salts were eluted. Protein recovery was around 98% with both types of fibrinogen.
The protein-containing tubes from both columns were combined and freeze-dried.
At this time analytical ultracentrifugation 7 revealed a minor impurity that migrated slightly faster than the fibrinogen peak. In order to improve the purity, both fibrinogens were chromatographed at room temperature on an ion exchange resin (CG-50) column. Before chromatography, the dried fibrinogen preparations were dissolved in 10 ml distilled water and dialysed for 3 hr at room temperature against 10 liter 0.05 M phosphate buffer, pH 7.0, with three buffer changes. Small amounts of insoluble protein were removed by centrifugation at 3000 g for 15 min at 250C.
Approximately 100 mg of protein was placed on an ion (Fig. 1 ) and the protein recovery ranged between 90 and 96%. The protein-containing tubes were combined and saturated ammonium sulfate solution was added to final concentration of 25%o (v/v) with additional stirring for 15 min at 20C.
The suspension was centrifuged at 3000 g for 15 min at 40C.
The precipitate was dissolved in about 8-10 ml of 0.9%o NaCl solution and dialysed overnight at room temperature against 10 liter of 0.9%7 NaCl solution, frozen in dry ice ethanol, and stored at -400 C. ments were run on the Spinco model E analytical ultracentrifuge using Schlieren optics (36) . The S-rates were determined on three dilutions in 0.1 M potassium phosphate buffer, pH 7.0, and extrapolated to infinite dilution. The sedimentation coefficient was then converted to standard conditions. The meniscus depletion method of Yphantis (37) was used for molecular weight determination. The three dilutions of normal and abnormal fibrinogen in 0.1 M potassium phosphate buffer, pH 7.0, were centrifuged at 12,619 rpm for 18 hr using interference optics for the molecular weight runs. Partial specific volume (V) of 0.718 was used for calculations (38) . In another experiment, the fibrinogen samples were treated with 5 M guanidine hydrochloride and then dialyzed against 5 M guanidine HCO, pH 5.5. Sedimentation velocities and molecular weights were then determined. For the molecular weight determinations, the samples were centrifuged at 15,-220 rpm for 13 hr with interference optics. A partial specific volume (V) of 0.696 was used for calculations (38) . In order to study the subunits of fibrinogens, following denaturation in 5 M guanidine HCl, cleavage with sodium sulfite was accomplished according to the method of Johnson and Mihalyi (38) and sedimentation velocities and molecular weights were determined in these samples. For molecular weight determinations, the samples were centrifuged at 32,603 rpm for 9 hr with interference optics and a partial specific volume (V) of 0.688 was used for calculations (38) .
In freshly purified fibrinogen samples, free SH groups were amperometrically titrated according to the methods published before (39, 40) . The amino acid analysis was performed according to the methods of Spackman, Stein and Moore (41) after hydrolysis for 22 hr. Protein-bound hexoses were measured by the method of Mokrasch (42) and hexosamine was determined by the method of Rimington (43) . Sialic acid was measured by the method of Ayala, Moore, and Hess (44) . Protein content was determined by the micro-Kjeldahl method (45) .
Polypeptide mapping of alpha (A) chain of the N-terminal fragments from normal and patient's fibrinogen were accomplished by the methods of Blomback et al. (46, 47 The plasma coagulation time, recalcification time, partial thromboplastin time, prothrombin time, and thrombin time were grossly prolonged, but normal levels of prothrombin, Ac-globulin, factor VIII, and antithrombin were found (Table I) . Euglobulin lysis time was normal. The level of profibrinolysin was 195 cU/ml (control 207 cU/ml) and the level of antifibrinolysin was 162 U/ml (control 176 U/ml). The patient's plasma clot was insoluble in 5 M urea solution.
No clottable fibrinogen could be determined in the patient's plasma with the method employed. Turbidometric measurements revealed 300 mg/100 ml fibrinogen in the patient's plasma, and the quantitative immunological (Fig. 2) indicating a normal rapid conversion of prothrombin to thrombin. The addition of normal human or bovine fibrinogen to the patient's plasma resulted in normal plasma recalcification time, partial thromboplastin time, and prothrombin time, further evidence that there was no disturbance in the activation of prothrombin to thrombin. But the clotting time for normal plasma or normal human fibrinogen by thrombin was inhibited by the addition of patient's plasma (Table II) prove the clotting of the patient's fibrinogen by thrombin (Table II) .
The plasma thrombelastogram tracings of the patient were grossly abnormal (Fig. 3) . The Immunologic testing of the patient's plasma fibrinogen presented certain unique features. A considerable amount of the fibrinogen-related molecules had a faster mobility than normal plasma fibrinogen on agar immunoelectrophoresis. The precipitin line formed principally in the region of alpha proteins to contrast with the beta-oriented arc formed by normal plasma fibrinogen (Fig. 4) . Also the precipitin band formed was less dense than the normal fibrinogen-antifibrinogen arc. On double diffusion in agar the patient's fibrinogen-antifibrinogen band was delayed in appearance, broader, and hazier than the normal to suggest two discrete populations of fibrinogen-related molecules (Fig. 5) . Neither complete intersection of precipitin lines nor spur formation occurred, but a region of low density or hazy interaction connected the patient's precipitin band with that of normal plasma. The interpretation that patient's fibrinogen and normal fibrinogen have in common a few, but not all, antigenic determinant groups seems reasonable from these data. Based on the coagulation data (abnormal thrombin times, low levels of clottable fibrinogen and abnormal thrombelastograms) associated with a bleeding tendency, we assume that the mother of our patient and her two brothers have partially normal and partially abnormal fibrinogen, whereas another sister (Mo. H.) has only abnormal fibrinogen molecules.
Immunoelectrophoresis on plasma from the two affected brothers and the mother gave similar patterns to P. H. They also required more time than normal for precipitin band formation in double diffusion plates. Plasma of both the mother and Al. H. revealed precipitin bands with indistinct areas, suggesting two populations of fibrinogen-related molecules, but these were much slower in development than in the patient (Fig. 6) (Fig. 7) . However, Detroit P. H. (Fig. 9) . A mol wet (MN average) of 292,034 +21,995 (SD) was calculated for normal fibrinogen (concentration, 0.0635 g/100 ml) and for the patient's fibrinogen (concentration, 0.095 g/100 ml) MN average of 309,065 +±10,416 (SD) was obtained. On extrapolation to zero and cleavage with sodium sulfite, saw, of 2.27 and 2.26 were obtained for normal and patient's fibrinogen, respectively. MN averages for these sulfitolysed fractions Protein-bound hexose, sialic acid and hexosamine were decreased in the patient's fibrinogen as compared to normal fibrinogen. Coefficient of variations for the different glycoproteins by the methods employed were as follows: protein-bound hexose, 4.5%; sialic acid, 6.5%; and hexosamine, 2.7%.
were 57,707 +4972 (SD) and 54,685 +2365 (SD) for normal and patient's fibrinogen, respectively. U-V absorption spectra of both fibrinogens in 0.1 M potassium phosphate buffer, pH 7.0, were identical and the absorption maxima was at 280 m1u. For denatured fibrinogens (5 M guanidine HCI, pH 5.5) the absorption maxima was at 275 mu. Fig. 11 shows the curves for the amperometric titration of free SH groups in the two samples. Approximately 3 moles of free SH groups/mole of freshly prepared fibrinogen were found in both cases.
In Table V the amino acid composition of normal fibrinogen and "Fibrinogen Detroit" is listed. The values for lysine, glucosamine, galactosamine, and possibly valine were lower in the patient's fibrinogen, as compared to normal fibrinogen when all the reported values in the literature are also considered. Table VI reveals that the protein-bound hexoses, hexosamine, and sialic acid were decreased in the patient's fibrinogen.
The analysis of the N-terminal disulfide knot of normal and abnormal fibrinogen has been published (47) and, therefore, the results will be presented here only briefly. Fibrinopeptide A and B were released from normal as well as abnormal cyanogen bromide-cleaved fibrinogen when thrombin or trypsin was used (47) .
After reduction with mercaptoethanol and alkylation with iodoacetic acid, marked differences were noted in the abnormal fibrinogen when the tryptic digests of the alpha (A) chain were subjected to two-dimensional electrophoresis-chromatography on thin-layer cellulose plates. Whereas with normal fibrinogen all of the expected fragments of the alpha (A) chain could be accounted for, peptide No. 9 was absent in the tryptic digest of the abnormal fibrinogen (47) . Further studies indicated that thrombin and trypsin had failed to cleave the alpha (A) chain of the abnormal fibrinogen between amino acids 19 and 20 and that No. 7 was composed of amino acids 17-23, rather than 20-23, as in normal fibrinogen (47) . Final analysis revealed that arginine at the 19th position in the alpha (A) chain was replaced by serine.
DISCUSSION
Congenital bleeding disorders related to fibrinogen can occur as afibrinogenemia or hypofibrinogenemia and dysfibrinogenemia. Both diseases are rare, although afibrinogenemia seems to occur more frequently than dysfibrinogenemia (49) . Whereas patients with afibrinogenemia usually suffer from severe spontaneous and posttraumatic hemorrhages (49) , patients with dysfibrinogenemia may not necessarily display a bleeding tendency (2, 7, 9) . This may in part account for the fact that only seven families with dysfibrinogenemia have been described, with the seventh one in this report.
The plasma coagulation studies of our patient (P. H.) and her sister (Mo. H.) were very similar to those found in patients with congenital afibrinogenemia. If one had relied on fibrinogen determinations with the clotting procedure (21) only, a wrong diagnosis could have derived. It is interesting to note that one family with dysfibrinogenemia (8) was originally described as hypofibrinogenemia. Electrophoresis of the plasma proteins usually allows a differentiation between afibrinogenemia and dysfibrinogenemia, because in afibrinogenemia the fibrinogen is completely absent or the traces require a special immunoelectrophbretic technique (50) . With turbidometric techniques or precipitation techniques one can always measure fibrinogen in plasma of patients with dysfibrinogenemia, but the amounts may be decreased (1, 2, 5, 8) .
Whole blood of patients with afibrinogenemia is usually uncoagulable, whereas patients with dysfibrinogenemia may have normal (5, 7, 8) , slightly prolonged (2), or markedly prolonged (our patient) whole blood coagulation time. Only in one instance the patient's whole blood did not clot at all (1) .
Congenitial afibrinogenemia has an autosomal recessive pattern of heredity, whereas in congenital dysfibrinogenemia the pattern is autosomal dominant (5, 8) . This seems to be in agreement with our family studies. The nine children of E. H. came from three fathers, none of whom were available for studies (Fig. 12) Prolonged plasma thrombin time seems to be a feature of most of the patients with dysfibrinogenemia (2, 5, 7, 8) . However, prolonged thrombin time is also observed in states of hyperfibrinolysis, and, in particular, when fibrinogenolysis occurs. Under these conditions fibrinogen breakdown products competetively inhibit the conversion of intact fibrinogen molecules to fibrin by thrombin (51, 52) . Moreover, the polymerization of the fibrin monomers is inhibited by these split products (52) (53) (54) . These fibrinogen fragments can be quantitatively determined by immunologic techniques in the patients' sera (23) . Although the amount of fibrinogen-related molecules in the serum of our patient P. H. exceeded normal levels, it seems unlikely that these represented fibrinolytic products. Since the abnormal fibrinogen of P. H. responded slowly to thrombin, most of these molecules probably remained in the "so-called" serum to react with antifibrinogen in the quantitative precipitin test.
Determination of fibrinogen by several techniques revealed that only the levels of clottable fibrinogen were markedly decreased in the plasma of three other family members, the mother (E. H.) and two brothers (S. H. and Al. H.). It was, however, unusual to find the grossly abnormal thrombin time associated with these fibrinogen levels. One explanation would be that abnormal fibrinogen molecules interfered with the clotting of normal fibrinogen molecules. This assumption seems to be supported by the observation that thrombin time of normal plasma was inhibited by the addition of our patient's (P. H.) plasma and that thrombin clotting time of purified normal fibrinogen was delayed by the addition of her plasma (Table II) . From these one might assume that the clotting disturbance in the abnormal fibrinogen lies in a defective polymerization of the fibrin monomers, rather than a defective release of either one or both of the fibrinopeptides A and B. This inhibitory effect of plasma of patients with dysfibrinogenemia on thrombin clotting time of normal plasma or fibrinogen has been observed previously by other investigators (2, 7), but "Fibrinogen Baltimore" does not show this effect (5) .
The Detroit family expressed certain unique immunologic qualities, but this family also bore some relationships to both Cleveland and Baltimore families. All shared some common antigenic determinants with one another and with both, normal plasma fibrinogen and purified fibrinogen. The that the presence of subunits should be certainly revealed in this solvent. However, the completely unfolded molecule of both the normal and the patient's fibrinogen sedimented in one single peak. Since only one component was present, one could conclude that either the molecule did not dissociate in this solvent, or that it dissociated into particles of equal weight. In the latter case, the largest possible particles would have been halves of the original molecule. Therefore, the observation that the apparent molecular weight in the approach to sedimentation-equilibrium studies was steeply rising above the half-molecular weight level provides a proof, in conjunction with the sedimentation-velocity studies, that fibrinogen did not dissociate in the concentrated guanidine solution. The sedimentation of fibrinogen in 5 M guanidine HCl was markedly affected by concentration, making the extrapolation of the sedimentation vs. concentration curve to infinite dilution very unreliable. This difficulty was circumvented by the reciprocal plots, as shown in Fig. 11 that was linear.
The sulfite-cleaved fibrinogen also appeared to be homogeneous, as shown in the sedimentation diagram (Fig. 9) , suggesting that the chains are of the same weight as one another. Most evidence in the literature indicate that normal bovine fibrinogen consists of six polypeptide chains of approximataely 56,000 mol wt (56) . Our results in the human are similar to the reported values, and these lie within the range of experimental errors. There was no evidence of subunits being loosely associated by noncovalent bonds. The polypeptides appear to be interlinked by disulfide bridges into a single unit.
The possible importance of the sulfur-containing groups in the different steps of blood coagulation has been considered in the past. It was suggested that the fibrinogen-fibrin conversion consisted of an aggregation of fibrinogen molecules due to the oxidation of their sulfhydryl groups and the formation of intermolecular disulfide bonds (57) , but no free SH groups could be demonstrated by various investigators (58) . Recently, however, Khomenko and Belitser (59) have demonstrated the presence of from 2 to 4 moles of free SH groups/mole of fibrinogen. Our results are similar to those of Khomenko and Belitser (59) . The failure to titrate free SH groups in the fibrinogen molecule by various investigators could be due to the fact that they can only be determined in freshly prepared samples. Our titration was accomplished within 4 hr of blood collection from the subjects. We also failed to titrate free SH groups in stored fibrinogen preparations.
Our studies have documented a specific molecular defect in the alpha (A) chain in the N-terminal disulfide knot of "Fibrinogen Detroit," in which arginine at the 19th position has apparently been replaced by serine (47) . Our studies also revealed a decreased carbohydrate content of "Fibrinogen Detroit." According to Laki and Mester (60) , an intact carbohydrate moiety is essential for polymerization of fibrin monomers and clot formation. The carbohydrates are apparently attached to the aspartic acid in the 52nd position from the N-terminal end of the gamma chain.8 Although no definite information is available concerning the sites of disulfide bridges in the N-terminal knot of the fibrinogen molecule, it seems possible that due to the primary defective amino acid substitution in the alpha (A) chain, a secondary effect on the molecular configuration may have taken place, resulting in the unavailability of binding sites for the carbohydrate in the gamma chain. The replacement of a strongly basic amino acid with a neutral hydroxy acid in the N-terminal portion of the alpha (A) chain may result in considerable conformational changes in the N-terminal disulfide knot of fibrinogen that could affect the "active site" for polymerization (46) . Inasmuch as the susceptibility of the No. 16 arginyl bond towards the action of thrombin was not altered by the substitution, at least in the cyanogen bromide-treated fibrinogen, it is likely that the polymerizaion stage that follows the release of the fibrinopeptide A was affected adversely, resulting in a severe bleeding disorder. The decreased lysine content in "Fibrinogen Detroit" may have been due to an incomplete hydrolysis of the protein, inasmuch as the hydrolysis was carried out for only 22 hr.
